Traders Buy Large Volume of GlaxoSmithKline Call Options (NYSE:GSK)

GlaxoSmithKline plc (NYSE:GSK) was the recipient of some unusual options trading on Wednesday. Stock traders acquired 133,747 call options on the company. This is an increase of 5,966% compared to the average daily volume of 2,205 call options.

NYSE:GSK opened at $43.85 on Friday. GlaxoSmithKline has a 12-month low of $36.41 and a 12-month high of $46.01. The company has a quick ratio of 0.56, a current ratio of 0.82 and a debt-to-equity ratio of 1.38. The firm has a market capitalization of $110.39 billion, a P/E ratio of 13.88, a P/E/G ratio of 2.92 and a beta of 0.70. The stock’s fifty day simple moving average is $43.22 and its 200-day simple moving average is $41.23.

GlaxoSmithKline (NYSE:GSK) last posted its quarterly earnings results on Wednesday, October 30th. The pharmaceutical company reported $0.95 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.85 by $0.10. GlaxoSmithKline had a return on equity of 92.73% and a net margin of 13.76%. The business had revenue of $11.57 billion for the quarter, compared to analyst estimates of $11.34 billion. As a group, equities research analysts expect that GlaxoSmithKline will post 3.13 earnings per share for the current year.

In other GlaxoSmithKline news, major shareholder Plc Glaxosmithkline purchased 357,142 shares of the company’s stock in a transaction that occurred on Friday, October 18th. The stock was purchased at an average cost of $28.00 per share, with a total value of $9,999,976.00. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Company insiders own 10.00% of the company’s stock.

Several large investors have recently bought and sold shares of the company. Berman Capital Advisors LLC boosted its position in shares of GlaxoSmithKline by 58.1% in the 2nd quarter. Berman Capital Advisors LLC now owns 656 shares of the pharmaceutical company’s stock worth $26,000 after purchasing an additional 241 shares during the last quarter. Sigma Planning Corp lifted its holdings in GlaxoSmithKline by 0.8% during the second quarter. Sigma Planning Corp now owns 32,090 shares of the pharmaceutical company’s stock worth $1,284,000 after acquiring an additional 250 shares in the last quarter. Hall Laurie J Trustee lifted its holdings in GlaxoSmithKline by 15.7% during the third quarter. Hall Laurie J Trustee now owns 1,842 shares of the pharmaceutical company’s stock worth $79,000 after acquiring an additional 250 shares in the last quarter. NTV Asset Management LLC lifted its holdings in GlaxoSmithKline by 1.7% during the third quarter. NTV Asset Management LLC now owns 15,287 shares of the pharmaceutical company’s stock worth $652,000 after acquiring an additional 250 shares in the last quarter. Finally, Trillium Asset Management LLC lifted its holdings in GlaxoSmithKline by 2.2% during the second quarter. Trillium Asset Management LLC now owns 11,519 shares of the pharmaceutical company’s stock worth $461,000 after acquiring an additional 252 shares in the last quarter. Institutional investors and hedge funds own 11.20% of the company’s stock.

Several equities research analysts have recently commented on the company. Citigroup reissued a “neutral” rating on shares of GlaxoSmithKline in a research note on Wednesday, November 6th. Argus lifted their target price on GlaxoSmithKline from $47.00 to $50.00 and gave the company a “buy” rating in a research note on Monday. JPMorgan Chase & Co. reissued a “neutral” rating on shares of GlaxoSmithKline in a research note on Thursday, October 17th. Jefferies Financial Group reissued a “buy” rating on shares of GlaxoSmithKline in a research note on Thursday, August 29th. Finally, New Street Research raised GlaxoSmithKline from a “reduce” rating to a “hold” rating in a research note on Wednesday, October 16th. One analyst has rated the stock with a sell rating, fourteen have given a hold rating and five have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $43.16.

GlaxoSmithKline Company Profile

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.

Recommended Story: How does the Beige Book influence monetary policy?

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.